Immunotherapies Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Immunotherapies stocks.

Immunotherapies Stocks Recent News

Date Stock Title
May 7 ACLX Arcellx to Participate in Two Upcoming Investor Conferences
May 7 ALPN Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Q1 2024 Earnings Call Transcript
May 7 ALPN Q1 2024 Vertex Pharmaceuticals Inc Earnings Call
May 7 EVAX Sidoti Events, LLC's Virtual May Micro-Cap Conference
May 7 ALPN Vertex Pharmaceuticals Inc (VRTX) (Q1 2024) Earnings Call Transcript Highlights: Strong Growth ...
May 7 ALPN Vertex Pharmaceuticals (VRTX) Q1 2024 Earnings Call Transcript
May 6 CGON CG Oncology: ASCO Play And Top-Line Data End Of 2024 Could Drive Further Value
May 5 GNLX Genelux Corporation's (NASDAQ:GNLX) market cap rose US$11m last week; individual investors who hold 54% profited and so did insiders
May 3 CGON CG Oncology reports data from Phase 3 bladder cancer study
May 3 CGON CG Oncology's Promising Bladder Cancer Treatment: Balancing Hope And Risk In Late-Stage Trials
May 3 GMAB Genmab A/S (NASDAQ:GMAB) Q1 2024 Earnings Call Transcript
May 3 CGON Cretostimogene Monotherapy Demonstrated 75.2% Complete Response Rate in High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
May 3 CGON Amgen Posts Upbeat Results, Joins OneSpan, Paylocity Holding, MercadoLibre And Other Big Stocks Moving Higher On Friday
May 2 GMAB Genmab A/S (GMAB) Q1 2024 Earnings Call Transcript
May 2 GMAB Genmab A/S 2024 Q1 - Results - Earnings Call Presentation
May 2 GMAB Genmab reports Q1 results
May 2 GMAB Genmab Announces Financial Results for the First Quarter of 2024
May 2 ALPN Earnings Preview: Alpine Immune Sciences, Inc. (ALPN) Q1 Earnings Expected to Decline
May 1 GMAB Genmab Q1 2024 Earnings Preview
Immunotherapies

Immunotherapy is the treatment of disease by activating or suppressing the immune system. Immunotherapies designed to elicit or amplify an immune response are classified as activation immunotherapies, while immunotherapies that reduce or suppress are classified as suppression immunotherapies.

In recent years, immunotherapy has become of great interest to researchers, clinicians and pharmaceutical companies, particularly in its promise to treat various forms of cancer.Immunomodulatory regimens often have fewer side effects than existing drugs, including less potential for creating resistance when treating microbial disease.Cell-based immunotherapies are effective for some cancers. Immune effector cells such as lymphocytes, macrophages, dendritic cells, natural killer cells (NK Cell), cytotoxic T lymphocytes (CTL), etc., work together to defend the body against cancer by targeting abnormal antigens expressed on the surface of tumor cells.
Therapies such as granulocyte colony-stimulating factor (G-CSF), interferons, imiquimod and cellular membrane fractions from bacteria are licensed for medical use. Others including IL-2, IL-7, IL-12, various chemokines, synthetic cytosine phosphate-guanosine (CpG) oligodeoxynucleotides and glucans are involved in clinical and preclinical studies.

Browse All Tags